📊 ALNY Key Takeaways
Is Alnylam Pharmaceuticals, Inc.. (ALNY) a Good Investment?
Alnylam demonstrates exceptional financial momentum with 65.2% revenue growth, transformative profitability improvements (net income +212.8% YoY), and strong cash generation (FCF of $465.4M). The company exhibits solid financial health with a current ratio of 2.76x, manageable leverage at 0.86x debt-to-equity, and robust interest coverage of 14.2x, positioning it well for sustained growth and operational flexibility.
Alnylam shows a major step-up in fundamentals, with revenue up 65.2% YoY, net income up 212.8%, and positive free cash flow of $465.38M, indicating that growth is translating into real earnings and cash generation. Liquidity is strong with $1.66B in cash and current and quick ratios above 2.7x, but the balance sheet still carries meaningful liabilities relative to equity, so the core story is strong execution with some balance-sheet sensitivity.
Why Buy Alnylam Pharmaceuticals, Inc.. Stock? ALNY Key Strengths
- Explosive revenue growth of 65.2% YoY indicating strong market traction and demand for pipeline products
- Outstanding earnings leverage with net income up 212.8% YoY and net margin of 8.4%, demonstrating significant operational leverage
- Healthy balance sheet with $1.7B cash, current ratio of 2.76x, and manageable debt-to-equity ratio of 0.86x
- Strong free cash flow generation of $465.4M with 12.5% FCF margin supporting dividend potential and R&D investments
- Superior liquidity metrics with quick ratio of 2.71x indicating ability to meet short-term obligations
- Exceptional ROE of 39.8% reflecting highly efficient capital deployment
- Revenue growth of 65.2% YoY with net income growth of 212.8% shows accelerating operating leverage
- Positive operating cash flow of $524.08M and free cash flow of $465.38M support higher-quality earnings
- Strong liquidity profile with $1.66B cash and current ratio of 2.76x reduces near-term funding risk
ALNY Stock Risks: Alnylam Pharmaceuticals, Inc.. Investment Risks
- Heavy reliance on pharmaceutical revenue with limited gross margin visibility in disclosed data
- Significant insider activity (27 Form 4 filings in 90 days) warrants monitoring for potential concern signals
- Operating margin of 13.5% compressed relative to net margin of 8.4% suggests elevated non-operating expenses or tax burden
- Long-term debt of $677.7M requires ongoing servicing despite strong cash flow generation
- Pharmaceutical sector exposure to regulatory changes, patent cliffs, and competitive pressures
- Stockholders' equity is relatively low at $789.18M versus $4.18B of liabilities, leaving less balance-sheet cushion
- Net margin of 8.4% and operating margin of 13.5% are improved but still not especially high for a successful pharmaceutical business
- Long-term debt of $677.72M and debt-to-equity of 0.86x warrant monitoring if profitability weakens
Key Metrics to Watch
- Revenue growth sustainability and pipeline approval status
- Gross margin trends and product mix evolution
- Free cash flow consistency and cash conversion rate
- Debt reduction trajectory and leverage ratios
- Operating expense management and margin expansion potential
- R&D spending efficiency and pipeline advancement
- Operating margin and net margin sustainability
- Free cash flow and cash balance relative to debt and liabilities
Alnylam Pharmaceuticals, Inc.. (ALNY) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.76x current ratio provides a solid financial cushion.
ALNY Profit Margin, ROE & Profitability Analysis
ALNY vs Healthcare Sector: How Alnylam Pharmaceuticals, Inc.. Compares
How Alnylam Pharmaceuticals, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Alnylam Pharmaceuticals, Inc.. Stock Overvalued? ALNY Valuation Analysis 2026
Based on fundamental analysis, Alnylam Pharmaceuticals, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Alnylam Pharmaceuticals, Inc.. Balance Sheet: ALNY Debt, Cash & Liquidity
ALNY Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Alnylam Pharmaceuticals, Inc..'s revenue has grown significantly by 1,590% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3.52 indicates the company is currently unprofitable.
ALNY Revenue Growth, EPS Growth & YoY Performance
ALNY Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $500.9M | -$16.9M | $-0.87 |
| Q2 2025 | $659.8M | -$16.9M | $-0.13 |
| Q1 2025 | $494.3M | -$57.5M | $-0.44 |
| Q3 2024 | $500.9M | -$16.9M | $-0.87 |
| Q2 2024 | $318.8M | -$16.9M | $-0.13 |
| Q1 2024 | $319.3M | -$65.9M | $-0.52 |
| Q3 2023 | $264.3M | $147.8M | $1.15 |
| Q2 2023 | $224.8M | -$174.1M | $-2.21 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Alnylam Pharmaceuticals, Inc.. Dividends, Buybacks & Capital Allocation
ALNY SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Alnylam Pharmaceuticals, Inc.. (CIK: 0001178670)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ALNY
What is the AI rating for ALNY?
Alnylam Pharmaceuticals, Inc.. (ALNY) has a Combined AI Rating of BUY from Claude (STRONG BUY) and ChatGPT (BUY) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ALNY's key strengths?
Claude: Explosive revenue growth of 65.2% YoY indicating strong market traction and demand for pipeline products. Outstanding earnings leverage with net income up 212.8% YoY and net margin of 8.4%, demonstrating significant operational leverage. ChatGPT: Revenue growth of 65.2% YoY with net income growth of 212.8% shows accelerating operating leverage. Positive operating cash flow of $524.08M and free cash flow of $465.38M support higher-quality earnings.
What are the risks of investing in ALNY?
Claude: Heavy reliance on pharmaceutical revenue with limited gross margin visibility in disclosed data. Significant insider activity (27 Form 4 filings in 90 days) warrants monitoring for potential concern signals. ChatGPT: Stockholders' equity is relatively low at $789.18M versus $4.18B of liabilities, leaving less balance-sheet cushion. Net margin of 8.4% and operating margin of 13.5% are improved but still not especially high for a successful pharmaceutical business.
What is ALNY's revenue and growth?
Alnylam Pharmaceuticals, Inc.. reported revenue of $3.7B.
Does ALNY pay dividends?
Alnylam Pharmaceuticals, Inc.. does not currently pay dividends.
Where can I find ALNY SEC filings?
Official SEC filings for Alnylam Pharmaceuticals, Inc.. (CIK: 0001178670) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ALNY's EPS?
Alnylam Pharmaceuticals, Inc.. has a diluted EPS of $2.33.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ALNY a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Alnylam Pharmaceuticals, Inc.. has a BUY rating with 82% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is ALNY stock overvalued or undervalued?
Valuation metrics for ALNY: ROE of 39.8% (sector avg: 15%), net margin of 8.4% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy ALNY stock in 2026?
Our dual AI analysis gives Alnylam Pharmaceuticals, Inc.. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ALNY's free cash flow?
Alnylam Pharmaceuticals, Inc..'s operating cash flow is $524.1M, with capital expenditures of $58.7M. FCF margin is 12.5%.
How does ALNY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 8.4% (avg: 12%), ROE 39.8% (avg: 15%), current ratio 2.76 (avg: 2).
Why is ALNY's return on equity (ROE) so high?
Alnylam Pharmaceuticals, Inc.. has a return on equity of 39.8%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 8.4% net margin.